Quick Answer
ORAMED PHARMACEUTICALS INC. reported R&D Expense of $6.38 million for fiscal year 2025.
ORAMED PHARMACEUTICALS INC. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $6.38M | +0.9% |
| 2024 | $6.32M | -29.5% |
| 2023 | $8.97M | -67.5% |
| 2022 | $27.64M | +31.7% |
| 2021 | $20.99M | +105.1% |
| 2020 | $10.23M | -24.3% |
| 2019 | $13.52M | +12.9% |
| 2018 | $11.98M | +16.5% |
| 2017 | $10.28M | +33.4% |
| 2016 | $7.71M | +61.2% |
| 2015 | $4.78M | +45.9% |
| 2014 | $3.28M | +244.2% |
| 2013 | -$2.27M | -235.2% |
| 2012 | $1.68M | +45.0% |
| 2011 | $1.16M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $1.15M | -48.6% | +11.5% |
| June 30, 2025 | $1.03M | -28.3% | -53.1% |
| March 31, 2025 | $2.21M | +87.1% | -1.6% |
| September 30, 2024 | $2.24M | +134.3% | +55.5% |
| June 30, 2024 | $1.44M | -20.8% | +22.3% |
| March 31, 2024 | $1.18M | -73.4% | +23.2% |
| September 30, 2023 | $957.0K | -82.1% | -47.4% |
| June 30, 2023 | $1.82M | -80.2% | -58.9% |
- ORAMED PHARMACEUTICALS INC. showed an increase of +0.9% in R&D Expense compared to the prior fiscal year.
- Over the 2011–2025 period, ORAMED PHARMACEUTICALS INC.’s r&d expense has grown by 450.4% (from $1.16 million to $6.38 million).
- The most recent figure is from ORAMED PHARMACEUTICALS INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: